Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

Fig. 7

Pharmacokinetic and safety evaluation of hAB21 in cynomolgus monkey. Female cynomolgus monkeys were dosed twice, 1 week apart, with PBS (control), 10 or 30 mpk hAB21-Fcdead. Serum concentration of hAB21 (a) and occupancy of SIRPα on monocytes at the indicated time points in monkeys administered 10 mpk (b) and 30 mpk (c). Increase in soluble SIRPα over time in monkeys dosed with 10 or 30 mpk (d). Vertical dashed lines indicated infusion of monkey on day 8. e–h Hematology parameters of RBC (e), platelets (f), monocytes (g) and neutrophils (h)

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us